8635 W. 3rd St. Suite #485-W
Los Angeles, CA 90048
(310) 652-9162

Joel D. Mittleman, M.D.

Personal

Born in Los Angeles, California. Married, with two children.


Education

Undergraduate

University of California, Riverside, 1965-1969. B.A. Degree.

Medical

University of California, Los Angeles, 1969-1973. M.D. Degree.


Professional Training

Internship

Medical Intern, Mt. Zion Hospital and Medical Center, San Francisco, California, 1973-1974. Program director: Sid Levin, M.D.

Residency

Medical Resident, Mt. Zion Hospital and Medical Center, San Francisco, California, 1974-1976. Program director: Kenneth Woeber, M.D.

Fellowship

Fellow, Division of Nephrology and Hypertension, Harbor General Hospital/UCLA

School of Medicine, Torrance, California, 1976-1978.

Program Director: Richard Glassock, M.D.


Certification

Internal Medicine

Diplomate in Internal Medicine, American Board of Internal Medicine, 1976.

Nephrology

Diplomate in Nephrology, American Board of Internal Medicine, 1978.


Academic Honors

  • Phi Beta Kappa, University of California, 1968
  • Graduation with Highest Honors, University of California, Riverside, 1969.
  • Regents' Scholar, University of California, Los Angeles School of Medicine, 1969-1973
  • Assistant Clinical Professor, UCLA School of Medicine, 1979-2002
  • Associate Clinical Professor, UCLA School of Medicine, 2002-present

Publication

"Hypertension", a chapter in Handbook of critical Care ed. J.L. Berk and J.E. Sampliner. 2nd ed.; Boston, Little, Brown and Co., 1982; pp227-252.


Professional Organizations

  • American College of Physicians
  • American Kidney Foundation
  • American Society of Nephrology
  • International Congress of Nephrology

Professional Experience

  • Private practice, Internal Medicine and Nephrology, Los Angeles, California, 1978-present
  • Medical Director, Beverly Hills Dialysis Center, Los Angeles, California, 2008-present

Hospital Affiliation

  • Cedars-Sinai Medical Center, Los Angeles, California.
  • Midway Hospital, Los Angeles, California

Hospital Staff Offices

Beverly Hills Medical Center

Chairman, Credentials Committee, 1984-1986.

Beverly Hills Medical Center

Chief, Department of Medicine, 1986-1988

Cedars-Sinai Medical Center

Chairman, Inpatient Subcommittee, Nutrition Advisory and Support Committee, 1995-2001

Cedars-Sinai Medical Center

Chairman, Nutrition Advisory and Support Committee, 2001-2004


Hospital Committees

Beverly Hills Medical Center

Transfusion Committee, 1980-1982

Beverly Hills Medical Center

Credentials Committee, 1983-1986

Midway Hospital

Medical Education Committee, 1983-1989

Cedars-Sinai Medical Center

Dialysis and Transplant Committee, 1980-1988

Cedars-Sinai Medical Center

Library Committee, 1991-1992

Cedars-Sinai Medical Center

Nutrition Advisory Committee, 1989-1991; 1994-2004

Cedars-Sinai Medical Center

Nephrology Division, 1978-present.


Current and Prior Hospital Educational Activities

Midway Hospital

Coordinator and Lecturer, Midway Hospital CME Nephrology Lecture Series, 1982-1989.

Cedars-Sinai Medical Center

Discussant, Division of Urology "Stone Day", 1983.

Cedars-Sinai Medical Center

Lecturer, Department of Medicine Conference, 1983, 1985, 1992

Cedars-Sinai Medical Center

Lecturer Division of Nephrology Grand Rounds, 1986.

Cedars-Sinai Medical Center

Lecturer, Division of Gastroenterology Nutrition Lecture Series, 1991.

Cedars-Sinai Medical Center

Discussant, Department of Medicine CPC, 1992.

Cedars-Sinai Medical Center

Attending Physician, Inpatient Medical Teaching Service

Cedars-Sinai Medical Center

Lecturer, Nephrology Training Lecture Series

Cedars-Sinai Medical Center

Attending Physician, Metabolic Support Team

Cedars-Sinai Medical Center

Attending Physician, Renal Inpatient Rounds

Cedars-Sinai Medical Center

Guest Speaker, Pulmonary Fellow Conference, September 26, 1997


Clinical Study Location

  • Tower Nephrology Medical Group, Los Angeles, CA
  • DaVita Beverly Hills, Los Angeles, CA
  • DaVita Crescent Heights, Los Angeles, CA

Clinical Studies

2013 ICH Good Clinical Practice for Clinical Trial Sites (Certificates)

Sub-Investigator 2014 Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV, open Label, Multicenter Trial, with MRI Substudy, of Repeated Doses Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Definiency Anemia (IDA) in Chronic Kidney Disease (CDK) Patients on Hemodialysis
Sub-Investigator 2014 A Multicenter Single-arm Extention Study to Describe the Long- term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Sub-Investigator 2013 A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Seconday Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis.
Sub-Investigator 2013 ZS-003: “A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia.
Sub-Investigator 2013 Randomized, Double-blind, Parallel-group, Multicenter study to evaluate the efficacy and safety of HX575 Epoetin alfa cs. US licensed Epoetin alfa (Epogen/Procrit) in the treatment of anemia associated with chronic kidney disease.
Sub-Investigator 2013 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137
Sub-Investigator 2012 A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type 2 Diabetic Subjects with Nephropathy
Sub-Investigator 2011 A Three-Period, 58-Week Safety and Effiancy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis
Sub-Investigator 2011 Bardoxolone Methyl Evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (Beacon)
Sub-Investigator 2011 A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study
Sub-Investigator 2010

A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease.

Sub-Investigator 2009

A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor.

Sub-Investigator 2008

Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia.

Sub-Investigator 2007

A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin

Sub-Investigator 2007

Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis

Principal Investigator 2007

A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®)

Sub-Investigator 2007

A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections.

Sub-Investigator 2007

Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis.

Sub-Investigator 2007

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease.

Sub-Investigator 2007

A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease

Sub-Investigator 2007

An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency

Principal Investigator 2006

Arandomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy.

Principal Investigator 2006

Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events.

Sub-Investigator 2006

A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis.

Sub-Investigator 2005

An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease.

Sub-Investigator 2004

Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis.

Principal Investigator 2004

Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis.

Sub-Investigator 2003

Phase 3 Cinacalcet open label to reach K/DOQI levels

Sub-Investigator 2003

Phase 3 trial in treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalce.

Sub-Investigator 2003

Phase 4 Prospective, Randomized, double-blind, double-dummy, forced- titration, multicenter, parallel group, one year treatment trial to compare MICARDIS (telmisartan) 80 mg versus COZAAR (losartan) 100mg, in hypertensive type 2 diabetic patients with overt nephropathy (AMADEO Study)

Sub-Investigator 2003

Phase 3 Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent When Two Different Vitamin D Regimens are used in Subjects with Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

Sub-Investigator 2002

Phase 4 to evaluate subject preference for Aranesp administered administered once monthly, ie every 4 weeks (Q4W) or procrit administered once weekly (QW).

Sub-Investigator 2002

Phase 3 Placebo-controlled, Double-blind, Extension Study to Assess the Long-term Safety of an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease.

Sub-Investigator 2002

Phase 4 Disease/Case Management of Patients Receiving ARANESP (darbepoetin alfa) to Treat the Anemia of Chronic Renal Insufficiency (CRI).

Sub-Investigator 2002

Phase 4, Multicenter Trial Using Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) and Iron Guided Algorithms to Treat Subjects with Anemia of Chronic Renal Insufficiency (CRI).

Sub-Investigator 2002

Phase 4 Multicenter Study Evaluating Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) in subjects with Anemia of Chronic Renal Insufficiency (CRI).

Sub-Investigator 2002

Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent on Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis.

Sub-Investigator 2001

Phase 3 A Multicenter, Open-label Extension Study to Assess the Long- term Safety and Efficacy if an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

Sub-Investigator 2001

Phase 2 Randomized, double-blind Study to Assess the Efficacy and safety of an Oral Calcimimetic Agent on secondary Hyperparathyroidism of End Stage Renal Disease treated with Hemodialysis.

Sub-Investigator 2000

Phase 2 Pharmacokinetic (PK) Analysis of Chronic Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) Therapy in Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis (HD).

Sub-Investigator 1999

Chronic Renal Insufficiency registry in a prospective, observational study designed to gather data on the use of various interventions delivered to patients with renal insufficiency, pre-ESRD.

Sub-Investigator 1999

Randomized Study Comparing the Efficiency of Once Weekly Versus 3 Times Weekly Administration of Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) to Subjects with End-Stage Renal Disease (ESRD) Receiving Hemodialysis.

Sub-Investigator 1998

Nabi Staphylococcal Vaccine Study

Sub-Investigator 1976

Sandoz Drug Study, "Evaluation of the safety and efficacy of LB46 in the treatment of severe hypertension"

Sub-Investigator 1970

Summer Student Research Fellow, Cedars-Sinai Medical Center Renal Division, Los Angeles, California, 1970